Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-05-30
1998-06-30
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514826, 514825, 514885, A61K 3170, C07H 19167
Patent
active
057736030
ABSTRACT:
The present invention relates to adenosinedeaminase inhibitors containing at least one O-alkylated moiety derivative and the pharmaceutically acceptable salts thereof. The pharmaceutical compositions of the present invention include adenosinedeaminase inhibitors containing at least one of the compounds represented by Formula (I): ##STR1## wherein each of R.sub.1, R.sub.2, and R.sub.3 are the same or different and is hydrogen or alkyl;
REFERENCES:
patent: 4808587 (1989-02-01), Go et al.
patent: 4808618 (1989-02-01), Go et al.
patent: 4843066 (1989-06-01), Yamada et al.
patent: 4985409 (1991-01-01), Yamada et al.
J. G. Niedzwicki, et al, "Structure-Activity Relationship of Ligands of Human Plasma Adenosine Deaminase.sub.2 ", Biochemical Pharmacology, vol. 41, No. 11, 1991, pp. 1615-1624.
The 1991 Sigma Chemical Company Catalog, St. Louis, MO, pp. 41 and 660.
Phillis, et al., "Brain Adenosine and Transmitter Amino Acid Release from the Ischemic Rat Cerebral Cortex: Effects of the Adenosine Deaminase Inhibitor Deoxycoformycin", Journal of Neurochemistry, vol. 56, No. 2, pp. 644-650 (1991).
Cristalli, et al., "Adenosine Deaminase Inhibitors: Synthesis and Structure-Activity Relationships of 2-Hydroxy-3-nonyl Derivatives of Azoles", J. Med. Chem., vol. 37, pp. 201-205 (1994).
Zhu, et al., "Protective effects of an adenosine deaminase inhibitor on ischemia-reperfusion injury in isolated perfused rat heart", Am. J. Physiol., vol. 259, H835-H838 (1990).
Kato, et al., "Effects of Antiasthma Drugs on Superoxide Anion Generation from Human Polymorphonuclear Leukocytes or Hypoxanthine-Xanthine Oxidase System", Int. Arch. Allergy Appl. Immunol., vol. 96, pp. 128-133 (1991).
2658. Cromolyn, The Merck Index, 12th edition, p. 439.
Richard, et al., "Open clinical study of liposomal superoxide dismutase in severe rheumatoid arthritis. Study of a series of 7 cases." Therapie (France), Jul.-Aug. 1989, 44(4), pp. 291-295.
Dejica, et al., "Local treatment with Epurox (superoxide dismutase and catalase of human origin) in the chronic inflammatory and degenerative rheumatism", Arch. Roum. Pathol. Exp. Microbiol. (Romania), Jul.-Dec. 1986, 45(3-4), pp. 299-310.
Corvetta, et al., "Rifamycin and superoxide dismutase in the treatment of rheumatoid synovitis of the knee", Recenti Prog. Med. (Italy), May 1985, 76(5), pp. 265-268.
Pasquier, et al., "Superoxide dismutases in polymorphonuclear leukocytes from patients with ankylosing spondylitis or rheumatoid arthritis", Clin. Exp. Rheumatol. (Italy), Apr.-Jun. 1985, 3(2), pp. 123-126.
Camus, et al., "Superoxide dismutase and rheumatoid arthritis. Study of a series of 6 cases.", Rev. Rhum. Mal. Osteoartic (France), Jul.-Sep. 1980, 47(7-9), pp. 489-492.
Rockwell et al. Mol. Pharmacol. 2:574-584, 1966.
Martin et al. Arzneim.-Forsch/Drug Res. 28 (I) Hefr 5, pp. 770-782, 1978.
The Merck Index, Tenth Edition, published by The Merck & Co., Inc., Rahway, N.J., 1983, pp. 762-763.
Kunz Gary L.
Nippon Zoki Pharmaceutical Co. Ltd.
LandOfFree
Method for treating allergic diseases with adenosine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating allergic diseases with adenosine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating allergic diseases with adenosine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1860986